Articles - GLP1 drugs changing weight loss and Life & Health insurance


Weight-loss injectables like Wegovy or Ozempic are gaining popularity amid an escalating global obesity crisis. Since 1975, worldwide obesity rates have nearly tripled, with projections indicating that over half of the global population will be overweight or obese by 2035. John Schoonbee, Global Chief Medical Officer, and Adam Strange, Life & Health R&D Manager, elaborate on the impact of GLP-1 drugs on weight loss, metabolic health and insurance. These medications influence risk factors such as insulin resistance, cardiovascular disease, and cancer. Additionally, they discuss the implications of these drugs on Life & Health insurance, including life, critical illness, and disability income, as well as future underwriting risk assessments.

 

Back to Index


Similar News to this Story

AI and pensions affecting life expectancy
Since the mid-1800s, U.K. life expectancy has consistently increased despite the occasional shocks from major global pandemics or wars. Since the earl
Four ways to optimise your salary sacrifice arrangement
Salary sacrifice schemes, also known as salary exchange, which enable employees to receive some of their pay in the form of a non-cash benefit, have l
The changing risk that comes with changing cars
Both new and used car sales are growing, according to the latest Society of Motor Manufacturers and Traders (SMMT) data(1) . In all, around 8 million

Site Search

Exact   Any  

Latest Actuarial Jobs

Actuarial Login

Email
Password
 Jobseeker    Client
Reminder Logon

APA Sponsors

Actuarial Jobs & News Feeds

Jobs RSS News RSS

WikiActuary

Be the first to contribute to our definitive actuarial reference forum. Built by actuaries for actuaries.